1. Home
  2. LXRX vs LZM Comparison

LXRX vs LZM Comparison

Compare LXRX & LZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • LZM
  • Stock Information
  • Founded
  • LXRX 1995
  • LZM 2021
  • Country
  • LXRX United States
  • LZM Isle of Man
  • Employees
  • LXRX N/A
  • LZM N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • LZM Metal Mining
  • Sector
  • LXRX Health Care
  • LZM Basic Materials
  • Exchange
  • LXRX Nasdaq
  • LZM Nasdaq
  • Market Cap
  • LXRX 428.8M
  • LZM 371.9M
  • IPO Year
  • LXRX 2000
  • LZM N/A
  • Fundamental
  • Price
  • LXRX $1.13
  • LZM $4.68
  • Analyst Decision
  • LXRX Buy
  • LZM Strong Buy
  • Analyst Count
  • LXRX 5
  • LZM 1
  • Target Price
  • LXRX $3.23
  • LZM $14.00
  • AVG Volume (30 Days)
  • LXRX 1.8M
  • LZM 92.5K
  • Earning Date
  • LXRX 11-11-2025
  • LZM 08-11-2025
  • Dividend Yield
  • LXRX N/A
  • LZM N/A
  • EPS Growth
  • LXRX N/A
  • LZM N/A
  • EPS
  • LXRX N/A
  • LZM N/A
  • Revenue
  • LXRX $58,432,000.00
  • LZM $416,323.00
  • Revenue This Year
  • LXRX N/A
  • LZM $611.56
  • Revenue Next Year
  • LXRX N/A
  • LZM $344.44
  • P/E Ratio
  • LXRX N/A
  • LZM N/A
  • Revenue Growth
  • LXRX 1504.83
  • LZM N/A
  • 52 Week Low
  • LXRX $0.28
  • LZM $2.90
  • 52 Week High
  • LXRX $2.18
  • LZM $7.29
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 50.83
  • LZM 55.89
  • Support Level
  • LXRX $1.03
  • LZM $4.36
  • Resistance Level
  • LXRX $1.15
  • LZM $4.75
  • Average True Range (ATR)
  • LXRX 0.06
  • LZM 0.21
  • MACD
  • LXRX -0.01
  • LZM 0.02
  • Stochastic Oscillator
  • LXRX 50.00
  • LZM 76.22

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.

Share on Social Networks: